Xyall lands €7.6M to expand automated pathology workflow
Xyall, an Eindhoven-based MedTech startup focused on automating tissue dissection for molecular pathology, has raised €7.6 million to support a global rollout of its laboratory solutions. The round was led by Capricorn Partners through its Capricorn Healthtech Fund II, with participation from existing backers Sioux Technologies, the Brabant Development Agency (BOM), Health Investment Partners, and several private investors.
Addressing a persistent bottleneck in molecular diagnostics
According to Guido du Pree, CEO and co-founder of Xyall, advances in PCR and next-generation sequencing have outpaced improvements in a key upstream step: selecting tumor tissue for molecular analysis. He said this step remains “largely manual, subjective, and imprecise,” positioning the company’s automated dissection systems as a bridge between morphological and molecular diagnostics.
Founded in 2018 by Guido du Pree and Hans van Wijngaarden, Xyall digitises and automates the workflow that starts with pathologists identifying Regions of Interest (ROIs) on H&E-stained slides and ends with technicians manually scraping tissue for downstream testing. The company argues this manual approach is time-consuming, hard to scale, and vulnerable to error and cross-contamination—pressures amplified by a global shortage of lab technicians.
Products and adoption
Xyall says its platform combines high-resolution slide imaging, image registration, workflow optimisation, and high-precision robotics to automate ROI determination and dissection. Its first product, the Tissector High Throughput System (launched 2021), targets large labs, holding up to 1,800 slides and processing more than 80 slides per hour with accuracy better than 0.1 mm. In 2023, it introduced the compact Tissector Table Top, designed for small to mid-sized labs.
The new funding will primarily support the global rollout of the Tissector Table Top, which the company says is already used in more than 15 molecular pathology laboratories, including tier-1 commercial, academic, pharma, and research institutions in the United States.
Related
